Asian guidelines for condyloma acuminatum

J Infect Chemother. 2022 Jul;28(7):845-852. doi: 10.1016/j.jiac.2022.03.004. Epub 2022 Mar 25.

Abstract

The present guidelines aim to provide comprehensive information on genital condyloma acuminata, including the epidemiology, clinical features, diagnosis and management. The guidelines provide evidence-based recommendations on the diagnosis, prevention and treatment of genital condyloma acuminata in adults in Asia, including patients with HIV co-infection.

Methodology: A PubMed search was performed, using the keywords "condyloma acuminata", "anal wart", "anogenital wart", "genital wart" and "genital HPV". A total of 3031 results were found in publications during last six years. A careful review of the titles and abstracts was done to find all the studies pertaining to epidemiology, clinical features, diagnosis, treatment and prevention of condyloma acuminata.

Diagnosis: Various diagnostic procedures described are: 1. PCR (LE: 2b). 2. Serology (LE: 2b). 3. In-situ hybridization (LE: 3).

Prevention: 1. Vaccination (LE: 1a): Quadrivalent vaccine reduced the frequency of anogenital warts in both vaccinated and unvaccinated contacts. According to the update Advisory Committee on Immunization Practices (ACIP) recommendations, the following protocol is recommended: (a). HPV vaccination at age 11 or 12 years for both males and females. (b). Catch-up vaccination for all persons through age 26 years. (c). Shared clinical decision-making regarding potential HPV vaccination for persons aged 27-45 years, who are at risk of new HPV infection. 2. Male circumcision (LE: 2a): conflicting evidence.

Hiv and condyloma acuminata: In HIV-affected individuals, the course of HPV is more aggressive, with a greater risk of treatment resistance, increased chances of intraepithelial neoplasia as well as cancers.

Treatment: Physician administered. 1. Photodynamic therapy (LE: 1a). 2. Laser (LE: 2b). 3. Surgery (LE: 1a). 4. Electrosurgery (LE: 2c). 5. Cryotherapy (LE: 1b). 6. Immunotherapy (LE: 1b). 7. Podophyllin (LE: 1b). Provider administered. 1. Imiquimod 5%(LE: 1a). 2. Podophyllotoxin (LE: 1b). 3. Sinecatechins (LE: 1a). 4. Cidofovir (LE: 3). 5. 5- Fluorouracil (LE: 1a). 6. Interferon (LE: 1a).

Keywords: Anal wart; Anogenital wart; Condyloma acuminata; Genital HPV; Genital wart.

Publication types

  • Review

MeSH terms

  • Adult
  • Antiviral Agents / therapeutic use
  • Child
  • Condylomata Acuminata* / drug therapy
  • Condylomata Acuminata* / therapy
  • Female
  • HIV Infections* / drug therapy
  • Humans
  • Imiquimod / therapeutic use
  • Male
  • Papillomavirus Infections* / diagnosis
  • Papillomavirus Infections* / prevention & control
  • Papillomavirus Vaccines* / therapeutic use

Substances

  • Antiviral Agents
  • Papillomavirus Vaccines
  • Imiquimod